JAMA vs Hepatology: Which Journal Should You Choose?

JAMA asks whether the liver paper matters across medicine. Hepatology asks whether the paper changes how the liver field thinks or practices.

That difference matters more than any headline metric.

If the manuscript depends on fibrosis staging logic, portal-hypertension context, transplant interpretation, or liver-specific biology to show its full force, Hepatology usually becomes more natural. If the consequence is broader and should matter well outside the liver field, JAMA becomes plausible.

JAMA wins when the liver study behaves like a broad medical paper.

That usually means:

• broad policy or public-health consequence
• cross-specialty relevance visible to general clinicians
• outcomes or care-delivery findings with significance beyond hepatology
• a manuscript whose claim lands without much liver-specific setup

That's consistent with JAMA's editorial guidance and with how the journal frames general-clinical importance.

Hepatology wins when the paper is elite liver research and the field is the right audience.

That includes:

• MASLD and steatohepatitis studies with real field consequence
• cirrhosis and portal-hypertension work
• viral hepatitis and transplant hepatology
• fibrosis, biomarkers, and liver-pathophysiology papers with clear liver relevance
• studies whose strongest implications are still liver-specific

Hepatology's editorial guidance is especially clear that the journal wants the liver angle to be central, not decorative.

Hepatology expects unmistakable liver specificity

submission's editorial guidance is direct that generic inflammation or metabolism stories with a liver wrapper are weak fits. That's useful because it shows how hard the journal screens for field identity.

JAMA is more comfortable with broad outcomes and policy framing

Liver-care delivery, screening, disparities, and health-system consequence can sometimes fit JAMA better than Hepatology when the audience genuinely extends beyond hepatologists.

Hepatology's reviewer pool is an advantage for liver-native logic

If the manuscript depends on disease-specific liver context, transplant nuance, or biomarker interpretation that general-medical reviewers may underweight, Hepatology gives the paper a much better reader fit.

JAMA is harsher on specialty confinement

If the paper only fully lands after a lot of liver-specific explanation, the general-medical case weakens quickly even when the science is good.

• the paper matters beyond hepatology
• broad clinical, policy, or public-health consequence is central
• general physicians or hospital leaders should care immediately
• the manuscript gets stronger when framed for medicine broadly

That's the narrower lane.

• the paper is clearly liver research, but very strong
• the ideal audience is still hepatologists and transplant teams
• liver-specific framing is part of the paper's strength
• the work changes how the field interprets disease, staging, prognosis, or therapy

That's often the more strategic first move.

This is a sensible cascade.

If JAMA rejects the paper because it's too specialty-specific, Hepatology is often the right next move.

That works especially well when:

• the science is strong
• the weakness was breadth, not quality
• the manuscript still clearly matters inside hepatology
• liver-specific context is actually part of the paper's value

It works less well when the paper is too narrow or too thin even for a flagship liver journal.

JAMA punishes specialty dependence

If the abstract only fully makes sense to liver specialists, the general-medical case usually weakens fast.

Hepatology punishes generic biology with a liver wrapper

source's editorial guidance are very clear here. Papers that feel like broad fibrosis, inflammation, or metabolism stories rather than real liver papers become vulnerable quickly.

MASLD and metabolic liver studies

These can go either way. If the consequence is broad across medicine or public health, JAMA gets stronger. If the value depends on liver-specific disease logic, Hepatology usually wins.

Cirrhosis and portal-hypertension work

These are much more natural Hepatology papers unless the result has unusually broad clinical consequence.

Transplant hepatology

This almost always strengthens the Hepatology case because the field context is part of the paper's force.

Liver biomarkers and mechanism-heavy studies

These rarely become JAMA papers unless the practical consequence is much broader than usual. Hepatology is much more natural when the evidence is mature enough.

A strong JAMA first page makes the broad clinical or policy consequence obvious before a reader needs much liver context.

A strong Hepatology first page can carry more field-specific language, but it still has to make the liver relevance and practical consequence visible quickly. The paper should look like a flagship liver submission, not a general biology paper repackaged for hepatology.

That difference is usually visible before submission.

Ask which sentence fits the manuscript better:

• "this changes what medicine broadly should do or think" points toward JAMA
• "this changes what hepatology should do or think" points toward Hepatology

That sentence is often enough to stop a wasted cycle.

Hepatology can be the better strategic choice when the manuscript's value depends on:

• liver-specific biology
• transplant or cirrhosis context
• fibrosis or staging logic
• disease-specific interpretation
• hepatology readers seeing why the paper matters now

In those cases, forcing the paper toward JAMA can flatten the specialist logic that makes the study persuasive in the first place.

Try explaining the study to two imaginary readers: a general internist and a hepatologist. If the internist mainly hears "interesting liver work," but the hepatologist immediately understands the treatment, staging, biomarker, or prognostic consequence, the paper is probably telling you that Hepatology is the more natural first home. That kind of reader-fit test is often more honest than abstract prestige comparisons.

It also protects against a common liver-journal mistake: broadening the rhetoric while leaving the evidence exactly where it started. If the data are still strongest as a liver story, the wiser move is usually to preserve that strength rather than to disguise it. That usually produces a cleaner cover letter and a cleaner first submission.

Send to JAMA first if:

1. the paper has clear broad-medical consequence
2. non-hepatologists should care immediately
3. the manuscript gets stronger when framed for medicine broadly

Send to Hepatology first if:

1. the paper is elite liver research
2. the real audience is still the liver field
3. liver-specific framing increases the manuscript's force
4. the work changes treatment, prognosis, staging, or interpretation inside hepatology